Diagnostic value Of Human Trophoblastic Transmembrane Glycoprotein (TROP-2) Expression In Diagnosing Papillary Thyroid Carcinoma Immunohistochemical Study | ||
| Benha Medical Journal | ||
| Articles in Press, Accepted Manuscript, Available Online from 16 September 2025 PDF (1.13 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bmfj.2025.413016.2610 | ||
| Authors | ||
| Shimaa K. Abdelwahab1; Ahmed E.Badawy2; Nada M. Abdelhakiem* 3; Amr F. El-Sebaaie4; Eman A. Saad5 | ||
| 1Assistant Professor Of Pathology, Faculty of Medicine - Benha University | ||
| 2Professor of Pathology , Faculty of Medicine - Benha University | ||
| 3M.B.B. Ch, Faculty of Medicine, Benha University | ||
| 4Pathology consultant, Military Medical Academy and International Medical Center | ||
| 5Lecturer Of Pathology, Faculty of Medicine - Benha University | ||
| Abstract | ||
| Background: Diagnosis of papillary thyroid carcinoma (PTC) depends on characteristic histopathological features. However, there may be cases with inconsistent features, necessitating the use of immunohistochemical markers. IHC stains, such as HBME-1, galectin-3, and CK19, aid in the diagnosis of PTC; however, varying degrees of sensitivity and specificity have been reported. Recent studies have identified TROP-2 as a novel promising marker in the diagnosis of PTC. Aim: This study aimed to investigate the value of TROP-2 expression in the diagnosis of PTC and its differentiation from benign thyroid lesions and low-risk neoplasms (NIFTP). Material and methods: This retrospective study was carried out on 51 cases classified according to the 5th edition of the WHO classification 2022 as follows: 13 benign thyroid lesion cases, 12 low-risk neoplasms (NIFTP) cases, and 26 papillary thyroid carcinoma cases. 6 cases of breast carcinoma were taken as a control. Clinicohistopathological parameters were correlated with TROP-2 expression. Results: In the current study, there was a positive, significant statistical correlation(P<0.01) between TROP-2 expression and the studied cases, as 7.7% of benign cases, 50% of low-risk neoplasms cases, and 92.3% of malignant cases were positive. Conclusion: TROP-2 may be a potentially valuable marker that can aid in the diagnosis of PTC and differentiate it from its benign mimics and low-risk neoplasms (NIFTP) with high sensitivity and specificity. | ||
| Keywords | ||
| Papillary thyroid carcinoma (PTC), Follicular variant-papillary thyroid carcinoma (FV-PTC); Human Trophoblastic Transmembrane Glycoprotein (TROP-2) | ||
|
Statistics Article View: 3 PDF Download: 1 |
||
